Health Checkup (I) | Guarding Women's Health Starts with a Gynecologic Cancer Dual-Screening — Double Protection for Your Checkup
When planning your annual health checkup, wouldn't you like to use a more efficient and comprehensive approach to address two important gynecologic health risks at once? Now, "simultaneous methylation testing for endometrial cancer (CISENDO®: CDO1/CELF4) and cervical cancer (CISCER®: PAX1/JAM3)" allows you — during your routine gynecological examination (where a physician gently collects cervical cells with a small brush) — using only this single collected sample, to additionally perform a sophisticated genetic test that simultaneously assesses your risk for both cervical cancer and endometrial cancer, essentially adding a "double safeguard" to your health.
Choosing "simultaneous methylation testing for endometrial cancer (CISENDO®: CDO1/CELF4) and cervical cancer (CISCER®: PAX1/JAM3)" brings you five important benefits:
1. Nationally Certified, Reliable and Reassuring
This is currently the only dual-test option — both the endometrial cancer (CISENDO®) and cervical cancer (CISCER®) methylation detection kits have been approved by the National Medical Products Administration — enabling simultaneous detection of endometrial cancer and cervical cancer using cervical cells. Its safety and accuracy have been rigorously certified.
2. Single Sampling, Dual Protection
In the past, endometrial cancer lacked convenient and effective early screening methods, often requiring invasive examinations only after symptoms appeared. Now, you simply add this one test to your routine cervical cancer screening — without the need for additional sampling — to simultaneously learn about your endometrial health. It saves time, effort, and is highly convenient.
3. Earlier Warning, Proactive Management
This test can detect early signs of potential cellular changes at the genetic level — before you experience discomfort (such as abnormal bleeding) or before ultrasound detects abnormalities — and can indicate the likely direction of the problem (cervical or uterine). This gives you valuable time for examination and intervention, truly achieving "prevention before disease occurs."
4. Relieving Anxiety, Precise Guidance
For women who have previously tested HPV-positive, this test provides clearer direction. If cervical indicators show low risk, it helps reduce unnecessary anxiety and excessive examinations; if high risk is indicated, it prompts you to pursue more targeted in-depth diagnosis — particularly able to uncover problems hidden within the endocervical canal that ordinary examinations may miss.
5. Suitable for Modern Women's Concerns About Endometrial and Reproductive Health
Endometrial cancer is trending toward younger age of onset. For women with relevant risk factors (such as obesity, diabetes) or whose endometrium is difficult to assess on ultrasound due to menstrual cycle or obesity, this test provides important genetic risk information during checkups. When results show low risk, it helps allay concerns and allows women with benign conditions to manage their health with greater peace of mind; when risk is indicated, it helps physicians make comprehensive judgments and determine whether further examinations such as hysteroscopy are needed, effectively avoiding missed diagnoses and enabling early intervention.
6. Summary
Combining CISENDO® and CISCER® — both nationally approved, highly accurate, registered test kits — with their efficient, early, and precise characteristics, is becoming a preferred option for modern women's health management. We recommend that at your next checkup, you proactively consult your physician about whether to add this "dual-cancer simultaneous screening" to your examination list.
Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology enterprise driven by innovative science and focused on health. CISPOLY is a pioneer in the field of early diagnosis of gynecologic tumors. With proprietary technology and patent-protected biomarkers at its core, the company has developed early diagnostic products for cervical cancer, endometrial cancer, ovarian cancer, and other gynecologic tumors, filling a void in this field.
As women pay increasing attention to their own health, the women's health market holds great promise. Beyond its gynecologic tumor early screening and diagnosis product line, CISPOLY will continue to build additional women's health-related product pipelines, striving to become a technology-innovation-driven leader in the women's health market.